On January 22, the "Phase I clinical study on the safety, tolerability, and preliminary efficacy of SG1408 for injection in patients with advanced malignant solid tumors" sponsored by CNBG Sumgen Biopharmaceuticals (Hangzhou) Co., Ltd. (hereinafter referred to as "CNBG Sumgen") completed the first dose for the first patient at the Phase I Clinical Study Center of Zhejiang Cancer Hospital. This marks another key milestone in the clinical study of SG1408, following the successful kick-off meeting held at Zhejiang Cancer Hospital on November 3.
Ms. Na Li, Vice President and Clinical Head of Sumgen Biotech and CNBG Sumgen, stated that SG1408 for injection is an innovative bispecific antibody targeting PD-L1/VEGF independently developed by CNBG Sumgen. It was approved by the National Medical Products Administration (NMPA) on September 26, 2022 for clinical trials in patients with advanced solid tumors. The project was able to overcome the impact of the COVID-19 pandemic and was quickly launched and advanced. Special thanks are given to Secretary Xiangdong Cheng and Director Zhengbo Song of Zhejiang Cancer Hospital, the leaders at all levels of the hospital, and CNBG for their strong support, as well as the project team for their joint efforts. We look forward to making further positive progress on this project and benefiting more cancer patients with everyone's collective effort.
The phase I clinical trial of SG1408 focuses on patients with relapsed or refractory advanced malignant solid tumors, including thoracic tumors (lung cancer, thymic cancer), gynecological tumors (cervical cancer, endometrial cancer), and gastrointestinal tumors (liver cancer, esophageal cancer, colorectal cancer). The project has been initiated at the Phase I Clinical Study Center of Zhejiang Cancer Hospital and will be launched in multiple sites soon. For more details, please consult us directly.
Copyright Rm. 301, F3, Building C, Block 2, No. 688, Bin'an Road, Changhe Zhejiang ICP Filing No. 18039044
